Hematopoietic stem cell transplantation for myelofibrosis

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Myelofibrosis with myeloid metaplasia (MMM) is a clonal hematopoietic stem cell disorder.
• Aberrant progenitor proliferation drives MMM, making it potentially curable via stem cell replacement.
• Current treatment challenges include disease-related factors and treatment-related mortality.

Purpose of the Study:

• To evaluate the efficacy and risks of allogeneic stem cell transplantation for myelofibrosis with myeloid metaplasia.
• To compare myeloablative and nonmyeloablative conditioning regimens in MMM treatment.
• To define criteria for recommending transplantation in MMM patients.

Main Methods:

• Review of outcomes for myeloablative allogeneic transplantation in MMM.
• Analysis of results from nonmyeloablative (reduced-intensity) conditioning regimens.
• Assessment of autologous transplantation for palliative roles.

Main Results:

• Myeloablative allogeneic transplantation achieves durable engraftment and cure in approximately 50% of MMM patients.
• Treatment failure is primarily due to treatment-related mortality, not disease recurrence, especially in older patients or those with advanced disease.
• Nonmyeloablative conditioning demonstrates encouraging engraftment rates and prolonged survival.

Conclusions:

• Allogeneic transplantation offers a curative option for MMM, balancing cure prospects against significant procedural risks.
• Transplantation is typically recommended for younger patients (under 50) with intermediate/high-risk disease or those aged 50-60 with limited life expectancy.
• Autologous transplantation may have a palliative role but is unlikely to be curative for MMM.